Issued: Wednesday, 28 October 2026, London, U.K.

Third quarter 2026 US dollar translation

This US dollar translation of the unaudited Results Announcement for 9 months 2026 should be read in conjunction with the Annual Report 2025, which was prepared in accordance with United Kingdom adopted International Financial Reporting Standards and has been prepared applying consistent accounting policies to those applied by the Group in the Annual Report 2025.

US Dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited.

Income statement

	9 months 2026 £m	9 months 2026 $m
TURNOVER	**24,925**	**33,400**
Cost of sales	**(6,531)**	**(8,752)**
Gross profit	**18,394**	**24,648**
Selling, general and administration	**(6,704)**	**(8,983)**
Research and development	**(7,141)**	**(9,569)**
Royalty income	**657**	**880**
Other operating income/(expense)	**(305)**	**(409)**
OPERATING PROFIT	**4,901**	**6,567**
Finance income	**109**	**146**
Finance expense	**(568)**	**(761)**
Share of after tax profit/(loss) of associates and joint ventures	**(9)**	**(12)**
PROFIT BEFORE TAXATION	**4,433**	**5,940**
Taxation	**(338)**	**(453)**
PROFIT AFTER TAXATION	**4,095**	**5,487**
Profit attributable to non-controlling interests	**380**	**509**
Profit attributable to shareholders	**3,715**	**4,978**
	4,095	**5,487**
EARNINGS PER SHARE	**92.5p**	**124.0c**
Diluted earnings per share	**91.1p**	**122.0c**

In the income statement above US dollar results for 9 months 2026 are calculated using average rates for the period

Issued: Wednesday, 28 October 2026, London, U.K.

Third quarter 2026 US dollar translation

In the detailed sales tables below US dollar results for nine months ended 30 September 2026 are calculated using average rates for the period

Sales tables

Specialty Medicines turnover – nine months ended 30 September 2026

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	$m	$m	$m	$m
HIV	**6,018**	**4,203**	**1,205**	**610**	**8,066**	**5,633**	**1,615**	**818**
Dolutegravir products	4,181	2,622	1,011	548	5,604	3,514	1,355	735
Dovato	2,169	1,218	673	278	2,907	1,632	902	373
Juluca	487	393	86	8	653	527	115	11
Tivicay	948	581	165	202	1,271	779	221	271
Triumeq	577	430	87	60	773	576	117	80
Long Acting Injectables	1,702	1,469	180	53	2,281	1,969	241	71
Apretude	403	387	4	12	540	519	5	16
Cabenuva	1,299	1,082	176	41	1,741	1,450	236	55
Other	135	112	14	9	181	150	19	12
Respiratory, Immunology & Inflammation	**3,164**	**2,064**	**519**	**581**	**4,240**	**2,766**	**695**	**779**
Benlysta	1,402	1,147	112	143	1,879	1,537	150	192
Exdensur	56	33	4	19	74	44	5	25
Nucala	1,676	884	410	382	2,246	1,185	549	512
Other	30	–	(7)	37	41	–	(9)	50
Oncology	**1,703**	**1,087**	**428**	**188**	**2,281**	**1,457**	**573**	**251**
Blenrep	109	55	35	19	146	74	47	25
Jemperli	753	543	145	65	1,009	728	194	87
Jideytro	3	3	–	–	4	4	–	–
Ojjaara/Omjjara	526	350	113	63	704	469	151	84
Zejula	319	136	141	42	427	182	189	56
Other	(7)	–	(6)	(1)	(9)	–	(8)	(1)
Specialty Medicines	**10,885**	**7,354**	**2,152**	**1,379**	**14,587**	**9,856**	**2,883**	**1,848**

Issued: Wednesday, 28 October 2026, London, U.K.

Third quarter 2026 US dollar translation

Vaccines turnover – nine months ended 30 September 2026

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	$m	$m	$m	$m
Shingles	**2,694**	**924**	**1,184**	**586**	**3,610**	**1,238**	**1,587**	**785**
Shingrix	2,694	924	1,184	586	3,610	1,238	1,587	785
Meningitis	**1,396**	**619**	**473**	**304**	**1,870**	**829**	**634**	**407**
Bexsero	972	315	466	191	1,303	422	625	256
Menveo	352	257	6	89	471	344	8	119
Penmenvy	47	47	–	–	63	63	–	–
Other	25	–	1	24	33	–	1	32
RSV	**452**	**138**	**176**	**138**	**606**	**185**	**236**	**185**
Arexvy	452	138	176	138	606	185	236	185
Influenza	**198**	**129**	**18**	**51**	**265**	**173**	**24**	**68**
Fluarix, FluLaval	198	129	18	51	265	173	24	68
Other Paediatric & Adult Vaccines	**2,276**	**1,050**	**559**	**667**	**3,050**	**1,407**	**749**	**894**
Boostrix	551	359	112	80	739	481	150	108
Hepatitis	496	246	152	98	665	330	204	131
Infanrix, Pediarix	384	228	83	73	515	306	111	98
Priorix, Priorix Tetra, Varilrix	246	54	103	89	329	72	138	119
Rotarix	419	151	88	180	561	202	118	241
Other	180	12	21	147	241	16	28	197
Vaccines	**7,016**	**2,860**	**2,410**	**1,746**	**9,401**	**3,832**	**3,230**	**2,339**

Issued: Wednesday, 28 October 2026, London, U.K.

Third quarter 2026 US dollar translation

General Medicines turnover – nine months ended 30 September 2026

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	$m	$m	$m	$m
Respiratory	**4,981**	**2,634**	**1,012**	**1,335**	**6,675**	**3,530**	**1,356**	**1,789**
Anoro Ellipta	405	137	191	77	543	184	256	103
Flixotide/Flovent	291	197	41	53	390	264	55	71
Relvar/Breo Ellipta	682	228	243	211	914	305	326	283
Seretide/Advair	574	187	121	266	769	251	162	356
Trelegy Ellipta	2,208	1,570	265	373	2,959	2,104	355	500
Ventolin	455	229	80	146	610	307	107	196
Other Respiratory	366	86	71	209	490	115	95	280
Other General Medicines	**2,043**	**128**	**479**	**1,436**	**2,738**	**172**	**642**	**1,924**
Blujepa	2	2	–	–	3	3	–	–
Other General Medicines	2,041	126	479	1,436	2,735	169	642	1,924
General Medicines	**7,024**	**2,762**	**1,491**	**2,771**	**9,412**	**3,701**	**1,998**	**3,713**

Commercial Operations turnover - nine months ended 30 September 2026

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	$m	$m	$m	$m
Commercial operations turnover	**24,925**	**12,976**	**6,053**	**5,896**	**33,400**	**17,389**	**8,111**	**7,900**

Issued: Wednesday, 28 October 2026, London, U.K.

Third quarter 2026 US dollar translation

Balance sheet

	30 September 2026 £m	30 September 2026 $m
ASSETS		
Non-current assets		
Property, plant and equipment	**9,431**	**12,543**
Right of use assets	**691**	**919**
Goodwill	**8,216**	**10,927**
Other intangible assets	**25,172**	**33,479**
Investments in associates and joint ventures	**49**	**65**
Other investments	**814**	**1,083**
Deferred tax assets	**6,735**	**8,958**
Derivative financial instruments	**54**	**72**
Other non-current assets	**2,642**	**3,514**
Total non-current assets	**53,804**	**71,560**
Current assets		
Inventories	**6,300**	**8,379**
Current tax recoverable	**302**	**402**
Trade and other receivables	**8,223**	**10,937**
Derivative financial instruments	**103**	**137**
Liquid investments	**28**	**37**
Cash and cash equivalents	**2,934**	**3,902**
Assets held for sale	**5**	**7**
Total current assets	**17,895**	**23,801**
TOTAL ASSETS	**71,699**	**95,361**
LIABILITIES		
Current liabilities		
Short-term borrowings	**(2,001)**	**(2,661)**
Contingent consideration liabilities	**(1,318)**	**(1,753)**
Trade and other payables	**(15,633)**	**(20,792)**
Derivative financial instruments	**(164)**	**(218)**
Current tax payable	**(678)**	**(902)**
Short-term provisions	**(926)**	**(1,232)**
Total current liabilities	**(20,720)**	**(27,558)**
Non-current liabilities		
Long-term borrowings	**(21,700)**	**(28,861)**
Deferred tax liabilities	**(1,670)**	**(2,221)**
Pensions and other post-employment benefits	**(1,552)**	**(2,064)**
Derivative financial instruments	**(101)**	**(134)**
Other provisions	**(751)**	**(999)**
Contingent consideration liabilities	**(5,311)**	**(7,064)**
Other non-current liabilities	**(1,532)**	**(2,038)**
Total non-current liabilities	**(32,617)**	**(43,381)**
TOTAL LIABILITIES	**(53,337)**	**(70,939)**
NET ASSETS	**18,362**	**24,422**
EQUITY		
Share capital	**1,349**	**1,794**
Share premium account	**3,507**	**4,664**
Retained earnings	**12,458**	**16,570**
Other reserves	**1,440**	**1,915**
Shareholders' equity	**18,754**	**24,943**
Non-controlling interests	**(392)**	**(521)**
TOTAL EQUITY	**18,362**	**24,422**

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 September 2026